| | | | ER + breast cancera | | | | ER- breast cancerb | | |
|---|
| User group of skincare products | n | Cancer cases | Age-adjusted HR (95% CI) | Multivariable HR (95% CI) | n | Cancer cases | Age-adjusted HR (95% CI) | Multivariable HR (95% CI) | pheterogeneityc |
|---|
| Non−/light users | 33,309 | 883 | 1.00 | 1.00 | 35,090 | 157 | 1.00 | 1.00 | |
| Moderate users | 22,411 | 585 | 0.98 (0.88,1.08) | 0.98 (0.89,1.09) | 23,475 | 92 | 0.89 (0.69,1.15) | 0.91 (0.7,1.18) | 0.58 |
| Frequent/heavy users | 35,784 | 948 | 0.99 (0.90,1.09) | 0.99 (0.90,1.08) | 37,896 | 159 | 0.95 (0.76,1.19) | 0.99 (0.79,1.23) | 0.99 |
- HR hazard ratio, CI confidence interval; ER: estrogen receptor
- aMultivariable adjusted for body mass index, smoking, age at first birth and parity combined, alcohol intake, physical activity, menopausal status, maternal breast cancer history and use of menopause hormone therapy
- bMultivariable adjusted for physical activity and maternal breast cancer history
- cTest of difference in effect by breast cancer subtypes
